摘要
目的分析临床中冠心病运用阿托伐他汀联合曲美他嗪的治疗效果。方法方便选择2017年10月—2018年10月间在该院治疗的120例冠心病患者进行研究,以随机数表法把患者分成两组,观察组运用阿托伐他汀联合曲美他嗪的联合用药进行治疗,参考组运用曲美他嗪进行治疗。对比两组临床的治疗效果,以及在治疗前和治疗后的心绞痛发作次数和持续时间以及血脂水平。结果观察组的治疗总有效率为91.67%,而参考组的治疗总有效率为68.33%,观察组显著优于对参考组,差异有统计学意义(χ^(2)=4.183,P<0.05)。治疗前心绞痛的发作次数和持续时间对比差异无统计学意义(P>0.05);治疗后,观察组心绞痛的发作次数和持续时间均优于参考照,差异有统计学意义(P<0.05);治疗前,两组患者的TC、TG、HDL-C、LDL-C水平对比差异无统计学意义(P>0.05);治疗后,观察组在治疗后血脂TC、TG、LDL-C水平显著低于参考组,HDL-C高于参考组的水平,差异有统计学意义(P<0.05)。结论在临床冠心病的治疗中运用阿托伐他汀联合曲美他嗪能够有效地降低心绞痛的发作和程度,并提升治疗的效果,改善患者的血脂水平,所以可以大量的推广应用。
Objective To analyze the clinical effect of atorstatin combined with trimetazidine in the treatment of coronary heart disease.Methods The 120 patients with coronary heart disease who were treated in the hospital between October 2017 and October 2018 were conveniently selected for the study.The patients were divided into two groups by a random number table.The observation group used the combination of atorvastatin and trimetazidine medication was used for treatment,and the reference group was treated with trimetazidine.The clinical treatment effects,as well as the number and duration of angina pectoris before and after treatment,as well as blood lipid levels of the two groups were compared.Results The total effective rate of treatment in the observation group was 91.67%,while that of the reference group was 68.33%.The observation group was significantly better than the reference group,and the difference was statistically significant(χ^(2)=4.183,P<0.05).There was no statistically significant difference in the number and duration of angina pectoris before treatment between the two groups(P>0.05);after treatment,the number and duration of angina pectoris in the observation group were better than the reference photos,and the difference was statistically significant(P<0.05);before treatment,there was no statistically significant difference in the levels of TC,TG,HDL-C,and LDL-C between the two groups of patients(P>0.05);after treatment,the observation group had significantly lower blood lipid levels of TC,TG,and LDL-C after treatment in the reference group,HDL-C was higher than that of the reference group,and the difference was statistically significant(P<0.05).Conclusion The use of atorvastatin combined with trimetazidine in the treatment of clinical coronary heart disease can effectively reduce the onset and degree of angina pectoris,enhance the effect of treatment,and improve the patient's blood lipid level,so it can be widely used.
作者
王海鹰
WANG Haiying(Department of Cardiology,Laizhou People's Hospital,Yantai,Shandong Province,261400 China)
出处
《中外医疗》
2021年第13期81-83,89,共4页
China & Foreign Medical Treatment
关键词
阿托伐他汀
曲美他嗪
联合用药
冠心病
效果
Atorstatin
Trimetazidine
Combination medication
Coronary heart disease
Effect
